NICE National Institute for Health and Care Excellence

NICE guidance

Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal)

Technology appraisal guidance
Published: 15 January 2025

www.nice.org.uk/guidance/ta1029

Contents

This guidance partially replaces TA697.

Advice

NICE is unable to make a recommendation about the use in the NHS of andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding in the skull (intracranial haemorrhage). This is because AstraZeneca has confirmed that it does not intend to make an evidence submission for the appraisal. AstraZeneca considers that currently there is not enough evidence that the technology is a cost-effective use of NHS resources in this population.

Information

If NHS organisations wish to consider andexanet alfa for this indication, they should follow the advice on rational local decision making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012. This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-6730-8